TR201903008T4 - Kollajen-aracılı hastalıkları tedavi etmek için uygun bileşimler. - Google Patents

Kollajen-aracılı hastalıkları tedavi etmek için uygun bileşimler. Download PDF

Info

Publication number
TR201903008T4
TR201903008T4 TR2019/03008T TR201903008T TR201903008T4 TR 201903008 T4 TR201903008 T4 TR 201903008T4 TR 2019/03008 T TR2019/03008 T TR 2019/03008T TR 201903008 T TR201903008 T TR 201903008T TR 201903008 T4 TR201903008 T4 TR 201903008T4
Authority
TR
Turkey
Prior art keywords
compositions suitable
mediated diseases
collagenase
treating collagen
drug product
Prior art date
Application number
TR2019/03008T
Other languages
English (en)
Inventor
L Sabatino Gregory
J Del Tito Benjamin Jr
J Bassett Phillip
A Tharia Hazel
G Hitchcock Antony
Yu Bo
L Wegman Thomas
Original Assignee
Biospecifics Tech Corporation
Endo Global Ventures
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biospecifics Tech Corporation, Endo Global Ventures filed Critical Biospecifics Tech Corporation
Publication of TR201903008T4 publication Critical patent/TR201903008T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1

Abstract

Colostridium histolyticum'dan hayli saflaştırılmış kollajenaz I'in ve kollajenaz II'nin bir kombinasyonunu içeren bir ilaç ürünü açıklanır. İlaç ürünü en az %95'ten daha fazla olan bir saflık ile, yaklaşık 1 ila 1'lik bir oranda kollajenaz I ve kollajenaz II içerir. Buluş ilaveten, söz konusu ilaç ürününü hazırlamak için iyileştirilmiş fermantasyon ve saflaştırma proseslerini açıklamıştır.
TR2019/03008T 2006-01-30 2007-01-30 Kollajen-aracılı hastalıkları tedavi etmek için uygun bileşimler. TR201903008T4 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76347006P 2006-01-30 2006-01-30
US78413506P 2006-03-20 2006-03-20
US11/699,302 US7811560B2 (en) 2006-01-30 2007-01-29 Compositions and methods for treating collagen-mediated diseases

Publications (1)

Publication Number Publication Date
TR201903008T4 true TR201903008T4 (tr) 2019-03-21

Family

ID=38328033

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/03008T TR201903008T4 (tr) 2006-01-30 2007-01-30 Kollajen-aracılı hastalıkları tedavi etmek için uygun bileşimler.

Country Status (17)

Country Link
US (15) US7811560B2 (tr)
EP (5) EP2474319A1 (tr)
JP (8) JP5309289B2 (tr)
KR (2) KR20110046537A (tr)
CN (2) CN101400788B (tr)
AU (2) AU2007211313C1 (tr)
BR (1) BRPI0708017A2 (tr)
CA (1) CA2637262C (tr)
DK (2) DK2474321T3 (tr)
ES (2) ES2709202T3 (tr)
HU (2) HUE041764T2 (tr)
IL (6) IL291175B2 (tr)
MX (1) MX2008009756A (tr)
NZ (2) NZ593907A (tr)
PT (2) PT1987141T (tr)
TR (1) TR201903008T4 (tr)
WO (1) WO2007089851A2 (tr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
EP2244735A4 (en) 2007-10-02 2011-02-23 Avaxia Biologics Inc ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
EP2130551B1 (en) * 2008-06-02 2012-06-06 Roche Diagnostics GmbH Improved purification of collagenases from clostridium histolyticum liquid culture
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
EP2403523A1 (en) 2009-03-06 2012-01-11 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
ES2385239B1 (es) 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
US10119131B2 (en) * 2011-03-16 2018-11-06 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
BR112014001439B1 (pt) 2011-07-20 2021-05-25 Mediwound Ltd. uso de um extrato proteolítico obtido de bromelaína para a preparação de um medicamento para o tratamento de uma doença do tecido conjuntivo
FI3581199T3 (fi) * 2011-10-21 2023-08-18 Endo Global Ventures Menetelmiä turvottavan fibroskleroottisen pannikulopatian hoitamiseksi tai vähentämiseksi
HUE057423T2 (hu) * 2012-01-12 2022-05-28 Endo Global Ventures Clostridium histolyticum enzim
ITPD20120118A1 (it) * 2012-04-18 2013-10-19 Fidia Farmaceutici "nuovo processo di produzione e purificazione dell'enzima collagenasi da vibrio alginolyticus"
JP2015521169A (ja) 2012-05-01 2015-07-27 プロテオリース リミテッド 抜歯する方法
BR102012013110A2 (pt) 2012-05-31 2014-05-27 Cristalia Prod Quimicos Farm Meio de cultura para bactérias do gênero clostridium livre de componentes de origem animal e processo para produção de sobrenadante contendo uma ou mais proteases com atividade colagenolítica e gelatinolítica
WO2014066622A2 (en) 2012-10-24 2014-05-01 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
US20160000890A1 (en) 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
DK2968484T3 (da) * 2013-03-15 2021-02-22 Biospecifics Tech Corporation Behandlingsfremgangsmåde og produkt til uterus fibromer, som anvender oprenset kollagenase
US9849133B2 (en) * 2013-06-18 2017-12-26 Eton Pharmaceuticals, Inc. Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US10383875B2 (en) 2013-06-18 2019-08-20 Harrow Ip, Llc Pharmaceutical formulations of xanthine or xanthine derivatives, and their use
US10117892B2 (en) * 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105412917B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗***癌的组合物及其用途
DE202014105440U1 (de) * 2014-11-12 2016-02-15 Bilz Werkzeugfabrik Gmbh & Co. Kg Werkzeugaufnahme
KR101723168B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
US10303245B2 (en) * 2015-05-04 2019-05-28 Adobe Inc. Methods and devices for detecting and responding to changes in eye conditions during presentation of video on electronic devices
CN115969318A (zh) 2017-03-01 2023-04-18 恩多风投有限公司 用于评估和治疗橘皮组织的装置和方法
AU2018244426A1 (en) * 2017-03-28 2019-10-17 Endo Ventures Limited Improved method of producing collagenase
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020058755A1 (en) 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
BR112021012675A2 (pt) 2019-01-06 2021-09-28 Endo Global Aesthetics Limited Formulação, formulação liofilizada, formulação reconstituída e kit
EP4045078A1 (en) 2019-10-15 2022-08-24 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
CA3236097A1 (en) 2022-01-05 2023-07-13 Jan HEYLAND Culture medium for cultivating hathewaya histolytica (or clostridium histolyticum) and the production of one or more proteases

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61289885A (ja) * 1985-06-14 1986-12-19 Nitta Zerachin Kk コラゲナ−ゼおよびコラゲナ−ゼの製造方法
JP2898022B2 (ja) * 1989-09-05 1999-05-31 株式会社ニッピ コラーゲン分解酵素の製造方法
CA2047306A1 (en) * 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) * 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
AU4644793A (en) * 1992-06-22 1994-01-24 Trigen, Inc. Molecular cloning of the genes reponsible for collagenase production from clostridium histolyticum
JP3186881B2 (ja) * 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
WO1996000283A1 (en) * 1994-06-24 1996-01-04 Boehringer Mannheim Corporation A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
BR9607143A (pt) * 1995-03-16 1997-11-25 Knoll Ag Enzima ibtenível de clostridium histolyticum mistura de enzimas uso da mistura uso de enzimas colagenase hp na forma pura colagenase az na forma pura e elastase na forma pura
US5989888A (en) 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
BR9713108A (pt) 1996-11-19 2004-06-22 Roche Diagnostics Gmbh Colagenase recombinante do tipo i de clostridium histolytucum e o uso da mesma para o isolamento de células e de grupos de células
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) * 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
ATE302844T1 (de) * 2001-07-02 2005-09-15 Nordmark Arzneimittel Gmbh & C Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms
EP1462519A1 (en) * 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) * 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
NZ576986A (en) * 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
US7355027B2 (en) * 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
PT1781697E (pt) * 2004-07-07 2009-06-25 Lundbeck & Co As H Nova epo carbamilada e método para a sua produção
EP1773400A2 (en) * 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
CA2593038C (en) * 2005-01-21 2015-03-17 Advance Biofactures Corporation Methods for treating adhesive capsulitis
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases

Also Published As

Publication number Publication date
EP3508571A1 (en) 2019-07-10
US20170087229A1 (en) 2017-03-30
JP6792596B2 (ja) 2020-11-25
BRPI0708017A2 (pt) 2011-05-17
US20100233151A1 (en) 2010-09-16
DK1987141T3 (en) 2019-03-25
IL291175A (en) 2022-05-01
KR20080093142A (ko) 2008-10-20
EP2474321A1 (en) 2012-07-11
US20230158127A1 (en) 2023-05-25
JP2017218452A (ja) 2017-12-14
IL192878A0 (en) 2009-02-11
IL277322A (en) 2020-10-29
MX2008009756A (es) 2008-12-18
NZ569882A (en) 2012-03-30
JP6944989B2 (ja) 2021-10-06
EP1987141A4 (en) 2009-11-18
IL277322B (en) 2022-04-01
AU2012200863B2 (en) 2014-08-28
PT2474321T (pt) 2019-07-25
US20110243919A1 (en) 2011-10-06
EP2474321B1 (en) 2019-04-17
IL254184B (en) 2019-02-28
US20110243908A1 (en) 2011-10-06
EP1987141B8 (en) 2019-03-06
IL291175B1 (en) 2023-10-01
WO2007089851A3 (en) 2008-01-03
IL254184A0 (en) 2017-10-31
JP2021113212A (ja) 2021-08-05
JP2020039371A (ja) 2020-03-19
CN101400788A (zh) 2009-04-01
NZ593907A (en) 2013-02-22
JP5309289B2 (ja) 2013-10-09
CN101400788B (zh) 2016-06-29
EP2474320A1 (en) 2012-07-11
AU2007211313C1 (en) 2014-05-22
JP2012070758A (ja) 2012-04-12
HUE044220T2 (hu) 2019-10-28
US20110243920A1 (en) 2011-10-06
IL291175B2 (en) 2024-02-01
EP2474319A1 (en) 2012-07-11
IL245434A0 (en) 2016-06-30
JP2017006143A (ja) 2017-01-12
IL264361B (en) 2020-09-30
KR20110046537A (ko) 2011-05-04
JP2018143258A (ja) 2018-09-20
US20100330065A1 (en) 2010-12-30
WO2007089851A2 (en) 2007-08-09
EP1987141B1 (en) 2018-12-05
HUE041764T2 (hu) 2019-05-28
JP6851943B2 (ja) 2021-03-31
PT1987141T (pt) 2019-03-04
JP6230200B2 (ja) 2017-11-15
US20070224183A1 (en) 2007-09-27
ES2729941T3 (es) 2019-11-07
US20110158972A1 (en) 2011-06-30
JP2009525283A (ja) 2009-07-09
AU2012200863A1 (en) 2012-03-08
US20160000889A1 (en) 2016-01-07
US20210106659A1 (en) 2021-04-15
CA2637262A1 (en) 2007-08-09
CA2637262C (en) 2014-08-19
US20110189163A1 (en) 2011-08-04
US20110189153A1 (en) 2011-08-04
IL264361A (en) 2019-02-28
US7811560B2 (en) 2010-10-12
CN105999244A (zh) 2016-10-12
JP7191152B2 (ja) 2022-12-16
AU2007211313B2 (en) 2011-12-01
CN105999244B (zh) 2022-01-11
JP2015128447A (ja) 2015-07-16
EP1987141A2 (en) 2008-11-05
IL245434A (en) 2017-10-31
IL192878A (en) 2013-03-24
ES2709202T3 (es) 2019-04-15
JP6389493B2 (ja) 2018-09-12
US20110243909A1 (en) 2011-10-06
DK2474321T3 (da) 2019-06-03
AU2007211313A1 (en) 2007-08-09
US20140004094A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
TR201903008T4 (tr) Kollajen-aracılı hastalıkları tedavi etmek için uygun bileşimler.
MY141972A (en) Biaryloxymethylarenecarboxylic acids
CL2012001056A1 (es) Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras.
TW200517389A (en) Biaryloxymethylarenecarboxylic acids
GB0625648D0 (en) Compounds
ATE419859T1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
NZ580226A (en) Dimer compounds as inhibitors of iap
GT200800184A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes.
UA98658C2 (uk) Циклічні депсипептиди
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
DE502006006107D1 (de) Amid substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
MX2009009176A (es) Inhibidores de serina-proteasas.
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
ATE485261T1 (de) Salicylsäurederivate
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
UY31460A1 (es) Procedimiento de preparacion de compuestos morfinicos
MX2010006211A (es) Proteínas elastasa recombinantes y métodos de fabricación y uso de las mismas.
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200716616A (en) Modulators of CCR-5 activity
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
GB0620255D0 (en) Antibody and uses thereof
MX349364B (es) Variante de alfa-1 antitripsina novedosa, método de preparación de la misma, y uso de la misma.
ATE517900T1 (de) Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ